ETON
Eton Pharmaceuticals Inc
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2018-11-09
$50.95
+0.14 (+0.28%)
last quote
Want the full multi-source brief on ETON?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$50.95
High
$52.68
Low
$50.51
Previous close
$50.81
Fundamentals
Market cap
$1.45B
P/E (TTM)
114.22x
P/S (TTM)
13.72x
P/B
17.34x
Gross margin
57.87%
Operating margin
15.44%
Net margin
12.02%
Rev growth (YoY)
81.49%
EPS growth (YoY)
—
ROE
40.13%
52W high
$66.37
52W low
$14.27
Beta
0.86x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-05todayafter market
Q3 2026EPS est $0.32Rev est $39.6M
Recent SEC filings
CIK 1710340filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 1d
ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?
Eton's Q3 growth is likely to have been driven by rising sales of Increlex, Alkindi Sprinkle and other key products, alongside contributions from recent launches.
ChartMill · 2d
ETON PHARMACEUTICALS INC (NASDAQ:ETON): High Growth Momentum Meets Breakout Setup
ETON Pharmaceuticals clears ChartMill's high growth momentum and breakout screen with a strong chart, 8 Setup Rating, and 7 Technical Rating.
Yahoo · 2d
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX®Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like growth factor1 (IGF-1) for infantile and epileptic spasmsResearch conducted at Baylor College of Medicine and Texas Children’s Hospital and funded by CURE Epilepsy and NIH, showed IGF-1 therapy led to red
Benzinga · 2d
Eton Pharmaceutical Announces New Development Program ET-900 Evaluating Mecasermin Injection For Treatment Of Infantile And Epileptic Spasms; Plans To Dose First Patient In Q1 2027
ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX®Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like growth factor1 (IGF-1)
Yahoo · 6d
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2026 financial results on Thursday, November 5, 2026. Management will host a conference call and live audio webcast to dis
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial